Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating

bizwiz2011 Free

04/04/23 10:34 AM

Post #13

tradewithzen Free

01/17/14 7:14 AM

Post #11

Here is my updated buy levels for NUVA

Rufus44

04/02/13 7:01 PM

Post #10

Looking forward to 2013 Q1 results!

Da Ghost

10/04/12 8:08 AM

Post #9

NUVA

what a thrill ! thanks eom smile

robust 16 volume

CowBoE

10/04/12 7:48 AM

Post #8

I think it will fall below $15

My new entry target is in $14's...

DAD2

10/04/12 6:37 AM

Post #7

New price target $16 after the downgrade

http://www.theflyonthewall.com/permalinks/entry.php/NUVAid1714185/NUVA-NuVasive-downgraded-to-Market-Perform-from-Outperform-at-JMP-Securities

DAD2

10/04/12 6:25 AM

Post #6

Someone just bought 3000 at $15.50 p/m Thursday am

CowBoE

10/03/12 11:03 PM

Post #5

Almost bought near $16.50 in AH.

Will wait at $.15s instead.

m177

10/03/12 5:18 PM

Post #4

Re: #3: @CowBoE - 25% drop after warning

NUVA big drop ah:

Co anticipates revenue for the third quarter 2012 to be approximately $147 million vs $153.8 mln consensus, which is below the Company's previous comments that suggested flat sequential revenue growth compared to $154.4 million in the second quarter 2012. NuVasive will announce complete revenue and earnings details related to the third quarter 2012 and will update guidance for the full year 2012 when the Company releases earnings on Monday, October 29, 2012, after the close of the market. Co says, "We experienced an unexpected sequential decline in the third quarter due to unusually high account churn related primarily to the growth of surgeon participation in physician-owned distributorships and to increasingly aggressive competitive tactics. As well, we heard from many surgeon customers of increased delays and denials from insurance payers. We believe our ability to take market share with innovative procedural solutions and services remains strong. We are focused on addressing the new challenges and will provide revised full year guidance on our October 29th earnings conference call."